Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2024
Spring on the Road
Spring Wellness 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Auction 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Supernus Pharmaceuticals, Inc.
< Previous
1
2
Next >
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
February 13, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
February 05, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Announces Third Quarter 2023 Financial Results
November 08, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus to Participate in the Jefferies London Healthcare Conference
November 07, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
November 02, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023
October 25, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey
October 16, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
October 09, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City
September 27, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms
September 09, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus to Participate in the Wells Fargo Healthcare Conference
August 31, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Bethany L. Sensenig Joins Supernus’ Board of Directors
August 21, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Announces Second Quarter 2023 Financial Results
August 08, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 8, 2023
July 24, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus to Participate in the Jefferies Healthcare Conference
May 31, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Announces First Quarter 2023 Financial Results
May 09, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus to Present at the Bank of America 2023 Health Care Conference
May 02, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 9, 2023
April 25, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Announces Repayment of Convertible Notes
April 03, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus to Participate in Two Upcoming Investor Conferences
March 08, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus to Present at the Cowen 43rd Annual Health Care Conference
March 01, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Announces Fourth Quarter and Full Year 2022 Financial Results
February 28, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Enters Into $150 Million Credit Facility
February 14, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023
February 09, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference
November 22, 2022
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus to Present at Two November Healthcare Conferences
November 08, 2022
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Announces Third Quarter 2022 Financial Results
November 08, 2022
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022
October 25, 2022
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Provides Regulatory Update on SPN-830
October 10, 2022
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.